A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
Clinical trial NCT03988036 · COMPLETED
Trial details
- NCT number
- NCT03988036
- Sponsor
- Women's Cancer Study Group GmbH
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-18
- Primary completion
- 2022-05-31
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.